Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it…
How Is The Market Feeling About Maximus?
Maximus’s (NYSE:MMS) short percent of float has risen 59.86% since its last report. The company recently reported that…
How Is The Market Feeling About Charles Schwab?
Charles Schwab’s (NYSE:SCHW) short percent of float has risen 8.14% since its last report. The company recently reported…
Peering Into American Airlines Gr’s Recent Short Interest
American Airlines Gr’s (NYSE:AAL) short percent of float has risen 56.34% since its last report. The company recently…
Top 3 Tech Stocks That May Fall Off A Cliff This Month
As of June 13, 2024, three stocks in the information technology sector could be flashing a real warning…
Over $105M Bet On This Oil Giant? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mostly higher on Wednesday, there were a few notable insider trades. When insiders purchase…
Netflix To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
‘Pop The Champagne Moment’ For Tesla? Analyst Says Shareholders Spoke Out Loud For Elon Musk: Here’s What To Expect At Thursday’s Annual Meeting
One of the overhangs that weighed on Tesla stock in recent sessions may have lifted but the company is still left to contend with a slew of fundamental challenges.
Datadog, Uber, S&P Global And More: CNBC’s ‘Final Trades’
Datadog clocked fiscal first-quarter revenue growth of 27% year-on-year to $611.3 million.